NASDAQ:DARE
Dare Bioscience, Inc.
Dare Bioscience, Inc.'s revenue grew 10429.4% in fiscal 2025 to $1.0M while operating margin rose to −1315.5%. Free cash flow was −$10.3M, −997.0% of revenue, and the diluted share count rose 31.6%.Summary generated from Dare Bioscience, Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$1.0M
Revenue growth+10429.4%
Revenue, 5-yr CAGRn/a
Gross margin71.3%
Operating margin−1315.5%
Net margin−1300.7%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$10.3M
FCF margin−997.0%
Share count change+31.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 10 | 3 | 0 | 1 |
| Operating income | −39 | −31 | −31 | −23 | −14 |
| Net income | −39 | −31 | −30 | −4 | −13 |
| Free cash flow | −29 | −18 | −39 | 5 | −10 |
Recent filings
- DEF 14AProxy statement
Oct 6, 2026 - 8-KNotice of delisting or listing-rule failure
Oct 2, 2026 - 8-KRegulation FD disclosure
Oct 1, 2026 - 8-KAmendment to articles or bylaws
Sep 11, 2026 - 8-KRegulation FD disclosure
Sep 9, 2026 - S-1Registration statement
Aug 26, 2026 - 8-KEntry into a material agreement
Aug 17, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026